CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0368 (clinicaltrials.gov NCT No: NCT00583622)
Title:Bevacizumab Combined With High-Dose Chemotherapy in Patients With Relapsed Ovarian Cancer
Principal Investigator:Yago Nieto
Treatment Agent:Bevacizumab; Carboplatin; Cyclophosphamide; Docetaxel; Gemcitabine; Melphalan; Topotecan
Study Status:Terminated
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Carboplatin
Cyclophosphamide
Docetaxel
Gemcitabine
Melphalan
Topotecan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:One 4-week admission
Supported By:N/A
Return Visit:Weekly during the first month, at D+100 and 6 month. Further evaluations can be
done by primary care provider.
Home Care:No home treatment required


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yago Nieto
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults